Lightstone portfolio company Reprieve Cardiovascular, who is pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, announced the completion of enrollment in the randomized pilot trial evaluating a first-of-its-kind personalized fluid management system for ADHF. Learn more about the “FASTR” trial: https://bit.ly/4dzngxz
We are excited to announce the completion of enrollment in the "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. The FASTR trial aims to compare the effectiveness of decongestive therapy administered by the Reprieve System with Optimal Diuretic Therapy in patients diagnosed with acute decompensated heart failure. Completing enrollment in the FASTR trial marks a significant milestone for Reprieve as we advance our mission to improve the lives of patients living with heart failure. Go here to learn more: https://lnkd.in/ehrB84_U